Voloridge Investment Management LLC lowered its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 11.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,579,960 shares of the biotechnology company's stock after selling 212,948 shares during the quarter. Voloridge Investment Management LLC owned approximately 0.76% of BioCryst Pharmaceuticals worth $11,881,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Xponance Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 9.1% in the 4th quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company's stock valued at $112,000 after acquiring an additional 1,242 shares during the period. Sei Investments Co. grew its position in BioCryst Pharmaceuticals by 2.8% during the 4th quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company's stock worth $430,000 after purchasing an additional 1,537 shares during the last quarter. Mariner LLC grew its position in BioCryst Pharmaceuticals by 32.1% during the 4th quarter. Mariner LLC now owns 13,258 shares of the biotechnology company's stock worth $100,000 after purchasing an additional 3,224 shares during the last quarter. Arizona State Retirement System increased its position in BioCryst Pharmaceuticals by 6.6% in the 4th quarter. Arizona State Retirement System now owns 57,001 shares of the biotechnology company's stock valued at $429,000 after acquiring an additional 3,518 shares during the period. Finally, Quantinno Capital Management LP raised its stake in shares of BioCryst Pharmaceuticals by 38.2% during the fourth quarter. Quantinno Capital Management LP now owns 14,828 shares of the biotechnology company's stock worth $112,000 after purchasing an additional 4,097 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.
BioCryst Pharmaceuticals Stock Performance
Shares of BioCryst Pharmaceuticals stock traded down $0.23 during trading on Wednesday, reaching $10.56. The company had a trading volume of 3,008,919 shares, compared to its average volume of 3,028,670. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $5.92 and a fifty-two week high of $11.11. The firm's fifty day moving average is $8.50 and its 200-day moving average is $8.09. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -17.31 and a beta of 1.08.
BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analysts' expectations of $126.64 million. During the same quarter in the prior year, the firm earned $0.28 EPS. The firm's quarterly revenue was up 40.8% compared to the same quarter last year. On average, research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. JPMorgan Chase & Co. upped their price target on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 6th. Finally, Cantor Fitzgerald initiated coverage on BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They set an "overweight" rating and a $20.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $16.56.
View Our Latest Stock Report on BCRX
About BioCryst Pharmaceuticals
(
Free Report)
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
See Also
Before you consider BioCryst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.
While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
